ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib, a multikinase inhibitor that targets BCR-ABL, Src family, c-KIT, PDGFR-β, and ephrin receptor approved for the treatment of chronic myelogenous leukemia (CML), has been investigated for the treatment of NSCLC.